Table 1.
Clinical and pathological characteristics of the entire cohort
| Variable | N | % |
|---|---|---|
| Age at diagnosis (years) | ||
| ≤ 50 | 66 | 75.00 |
| > 50 | 22 | 25.00 |
| BMI (Kg/m2) | ||
| ≤ 30 | 54 | 61.36 |
| > 30 | 34 | 38.64 |
| Diagnosis | ||
| Ductal | 76 | 86.36 |
| Lobular | 12 | 13.64 |
| Stage | ||
| 1 and 2 | 70 | 79.55 |
| 3 | 16 | 18.18 |
| 4 | 2 | 2.27 |
| Chemotherapy | ||
| No | 16 | 18.60 |
| Yes | 70 | 81.40 |
| Radiotherapy | ||
| No | 39 | 44.32 |
| Yes | 49 | 55.68 |
| Surgery | ||
| Lumpectomy | 43 | 48.86 |
| Mastectomy | 45 | 51.14 |
| Genetic mutation | ||
| Negative | 70 | 79.55 |
| BRCA1 | 13 | 14.77 |
| BRCA2 | 5 | 5.68 |
| ER positive | ||
| No | 39 | 44.32 |
| Yes | 49 | 55.68 |
| PR positive | ||
| No | 48 | 54.55 |
| Yes | 40 | 45.45 |
| HER2 positive | ||
| No | 70 | 79.55 |
| Yes | 18 | 20.45 |
| ER, PR, HER2 all negative | ||
| No | 57 | 64.77 |
| Yes | 31 | 35.23 |
| ER, PR positive & HER2 negative | ||
| No | 49 | 55.68 |
| Yes | 39 | 44.32 |